Tumor immune evasion arises through loss of TNF sensitivity
The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Whole-genome CRISPR screens identify resistance to TNF-mediated killing by T and NK cells as a tumor immune evasion mechanism.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“IFN γ and TNF α are key effector cytokines that contribute to anti-tumour immune responses 9,11,27-30 , and genes associated with IFN and TNF signaling pathways contribute to immune evasion 4,9,29 .”
From Targeting TBK1 to overcome resistance to cancer immunotherapy (2023) · cites this paper as [29]
In the citing paper
“Single-guide RNAs targeting genes involved in IFN γ sensing (Ifngr1, Ifgnr2, Jak1, Jak2, and Stat1) were enriched in control and Tbk1-null cells (Fig. 5d, Extended Data Fig. 10a), consistent with previous in vivo and in vitro screens 4,29 .”
From Targeting TBK1 to overcome resistance to cancer immunotherapy (2023) · cites this paper as [29]
Citations
Cites
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9
Doench, J. G., Fusi, N., Sullender, M., Hegde, M., Vaimberg, E. W., Donovan, K. F., Smith, I., Tothova, Z., Wilen, C., Orchard, R., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3437 · Cited by 4,637 · cited 1×
“The mouse cell lines MC38-Cas9, MC38OvaCas9, and B16Ova-Cas9 cells were transduced with the Brie genome-wide sgRNA library (40), and the human cell line MDA-MB-231 was transduced with the Brunello genome-wide sgRNA library.”
MethodMutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237 · cited 3×
“Gene mutations that reduce the efficacy of immunotherapy have recently been identified, including mutations in Janus kinases (JAK) providing resistance to anti–PD-1 therapy (9).”
BackgroundClonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
Li, W., Xu, H., Xiao, T., Cong, L., Love, M. I., Zhang, F., Irizarry, R. A., Liu, J. S., Brown, M., & Liu, X. S. (2014) · Genome Biology · doi:10.1186/s13059-014-0554-4 · Cited by 2,684
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
Shin, D. S., Zaretsky, J. M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A., Grasso, C. S., Hugo, W., Sandoval, S., Torrejon, D. Y., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1223 · Cited by 1,337
Perforin and granzymes: function, dysfunction and human pathology
Voskoboinik, I., Whisstock, J. C., & Trapani, J. A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3839 · Cited by 1,327
Self-citationGenome-scale CRISPR-Cas9 Knockout and Transcriptional Activation Screening
Joung, J., Konermann, S., Gootenberg, J. S., Abudayyeh, O. O., Platt, R. J., Brigham, M. D., Sanjana, N. E., & Zhang, F. (2017) · Nature Protocols · doi:10.1038/nprot.2017.016 · Cited by 1,243 · cited 1×
“Genomic DNA extraction was subsequently performed using the DNeasy Blood & Tissue Kit (Qiagen), and libraries were prepared as described previously (41).”
MethodIn vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target
Manguso, R. T., Pope, H. W., Zimmer, M. D., Brown, F. D., Yates, K. B., Miller, B. C., Collins, N. B., Bi, K., LaFleur, M. W., Juneja, V. R., et al. (2017) · Nature · doi:10.1038/nature23270 · Cited by 1,147
Cited by
Cancer immunoediting and resistance to T cell-based immunotherapy
O’Donnell, J. S., Teng, M. W. L., & Smyth, M. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0142-8 · Cited by 1,759
Saxena, M., van der Burg, S. H., Melief, C. J. M., & Bhardwaj, N. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00346-0 · Cited by 1,581
Melief, C. J. M., van Hall, T., Arens, R., Ossendorp, F., & van der Burg, S. H. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80009 · Cited by 1,164
Large-scale public data reuse to model immunotherapy response and resistance
Fu, J., Li, K., Zhang, W., Wan, C., Zhang, J., Jiang, P., & Liu, X. S. (2020) · Genome Medicine · doi:10.1186/s13073-020-0721-z · Cited by 1,067
Newton, K., Strasser, A., Kayagaki, N., & Dixit, V. M. (2024) · Cell · doi:10.1016/j.cell.2023.11.044 · Cited by 990
House, I. G., Savas, P., Lai, J., Chen, A. X. Y., Oliver, A. J., Teo, Z. L., Todd, K. L., Henderson, M. A., Giuffrida, L., Petley, E. V., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1868 · Cited by 790
“Given that mutations in both the JAK–STAT (73–75) pathway and in TNF signaling (76) have previously been reported as resistance mechanisms for immune checkpoint inhibitors, our data suggests that a failure to secrete CXCL9/CXCL10 by these tumors may represent an additional mechanism of immune escape.”
BackgroundSelf-citationBurr, M. L., Sparbier, C. E., Chan, K. L., Chan, Y.-C., Kersbergen, A., Lam, E. Y. N., Azidis-Yates, E., Vassiliadis, D., Bell, C. C., Gilan, O., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.08.008 · Cited by 649
Self-citationTargeting the epigenetic regulation of antitumour immunity
Hogg, S. J., Beavis, P. A., Dawson, M. A., & Johnstone, R. W. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0077-5 · Cited by 630
Self-citationSchumacher, T. N., Scheper, W., & Kvistborg, P. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042617-053402 · Cited by 574
Bock, C., Datlinger, P., Chardon, F., Coelho, M. A., Dong, M. B., Lawson, K. A., Lu, T., Maroc, L., Norman, T. M., Song, B., et al. (2022) · Nature Reviews Methods Primers · doi:10.1038/s43586-021-00093-4 · Cited by 571
Gasdermin E–mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome
Liu, Y., Fang, Y., Chen, X., Wang, Z., Liang, X., Zhang, T., Liu, M., Zhou, N., Lv, J., Tang, K., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.aax7969 · Cited by 566
The hallmarks of cancer immune evasion
Galassi, C., Chan, T. A., Vitale, I., & Galluzzi, L. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.09.010 · Cited by 565
Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells
Benmebarek, M.-R., Karches, C. H., Cadilha, B. L., Lesch, S., Endres, S., & Kobold, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061283 · Cited by 531
Synthetic lethality as an engine for cancer drug target discovery
Huang, A., Garraway, L. A., Ashworth, A., & Weber, B. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0046-z · Cited by 469
Wu, M., Huang, Q., Xie, Y., Wu, X., Ma, H., Zhang, Y., & Xia, Y. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01242-2 · Cited by 456
The present and future of the Cancer Dependency Map
Arafeh, R., Shibue, T., Dempster, J. M., Hahn, W. C., & Vazquez, F. (2025) · Nature Reviews Cancer · doi:10.1038/s41568-024-00763-x · Cited by 454
Genomic correlates of response to immune checkpoint blockade
Keenan, T. E., Burke, K. P., & Van Allen, E. M. (2019) · Nature Medicine · doi:10.1038/s41591-019-0382-x · Cited by 448
Functional genomic landscape of cancer-intrinsic evasion of killing by T cells
Lawson, K. A., Sousa, C. M., Zhang, X., Kim, E., Akthar, R., Caumanns, J. J., Yao, Y., Mikolajewicz, N., Ross, C., Brown, K. R., et al. (2020) · Nature · doi:10.1038/s41586-020-2746-2 · Cited by 443
Self-citationCRISPR in cancer biology and therapy
Katti, A., Diaz, B. J., Caragine, C. M., Sanjana, N. E., & Dow, L. E. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00441-w · Cited by 424
The TNF Paradox in Cancer Progression and Immunotherapy
Montfort, A., Colacios, C., Levade, T., Andrieu-Abadie, N., Meyer, N., & Ségui, B. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01818 · Cited by 305
Wu, L., Jin, Y., Zhao, X., Tang, K., Zhao, Y., Tong, L., Yu, X., Xiong, K., Luo, C., Zhu, J., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.07.001 · Cited by 284
Frangieh, C. J., Melms, J. C., Thakore, P. I., Geiger-Schuller, K. R., Ho, P., Luoma, A. M., Cleary, B., Jerby-Arnon, L., Malu, S., Cuoco, M. S., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00779-1 · Cited by 276
Zhang, Z., Wang, Z.-X., Chen, Y.-X., Wu, H.-X., Yin, L., Zhao, Q., Luo, H.-Y., Zeng, Z.-L., Qiu, M.-Z., & Xu, R.-H. (2022) · Genome Medicine · doi:10.1186/s13073-022-01050-w · Cited by 273
KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements
Zhang, S.-M., Cai, W. L., Liu, X., Thakral, D., Luo, J., Chan, L. H., McGeary, M. K., Song, E., Blenman, K. R. M., Micevic, G., et al. (2021) · Nature · doi:10.1038/s41586-021-03994-2 · Cited by 272
Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold
Vredevoogd, D. W., Kuilman, T., Ligtenberg, M. A., Boshuizen, J., Stecker, K. E., de Bruijn, B., Krijgsman, O., Huang, X., Kenski, J. C. N., Lacroix, R., et al. (2019) · Cell · doi:10.1016/j.cell.2019.06.014 · Cited by 259
(2022) · Nature Reviews Methods Primers · doi:10.1038/s43586-022-00098-7 · Cited by 250
Dufva, O., Koski, J., Maliniemi, P., Ianevski, A., Klievink, J., Leitner, J., Pölönen, P., Hohtari, H., Saeed, K., Hannunen, T., et al. (2020) · Blood · doi:10.1182/blood.2019002121 · Cited by 224
The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer
Vervoort, S. J., Welsh, S. A., Devlin, J. R., Barbieri, E., Knight, D. A., Offley, S., Bjelosevic, S., Costacurta, M., Todorovski, I., Kearney, C. J., et al. (2021) · Cell · doi:10.1016/j.cell.2021.04.022 · Cited by 219
Self-citationIn vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer
Dubrot, J., Du, P. P., Lane-Reticker, S. K., Kessler, E. A., Muscato, A. J., Mehta, A., Freeman, S. S., Allen, P. M., Olander, K. E., Ockerman, K. M., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01315-x · Cited by 218
Malireddi, R. K. S., Karki, R., Sundaram, B., Kancharana, B., Lee, S., Samir, P., & Kanneganti, T.-D. (2021) · ImmunoHorizons · doi:10.4049/immunohorizons.2100059 · Cited by 194
Ferroptosis‐Enhanced Cancer Immunity by a Ferrocene‐Appended Iridium(III) Diphosphine Complex
Wang, W., Ling, Y., Zhong, Y., Li, Z., Tan, C., & Mao, Z. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202115247 · Cited by 194
Tumor Necrosis Factor α Blockade: An Opportunity to Tackle Breast Cancer
Mercogliano, M. F., Bruni, S., Elizalde, P. V., & Schillaci, R. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00584 · Cited by 177
Targeting TBK1 to overcome resistance to cancer immunotherapy
Sun, Y., Revach, O.-Y., Anderson, S., Kessler, E. A., Wolfe, C. H., Jenney, A., Mills, C. E., Robitschek, E. J., Davis, T. G. R., Kim, S., et al. (2023) · Nature · doi:10.1038/s41586-023-05704-6 · Cited by 174
Liu, Y., Guo, Q., Yang, H., Zhang, X.-W., Feng, N., Wang, J.-K., Liu, T., Zeng, K., & Tu, P. (2022) · ACS Central Science · doi:10.1021/acscentsci.2c00107 · Cited by 167
CAR-T cell combination therapy: the next revolution in cancer treatment
Al-Haideri, M., Tondok, S. B., Safa, S. H., maleki, A. H., Rostami, S., Jalil, A. T., Al-Gazally, M. E., Alsaikhan, F., Rizaev, J. A., Mohammad, T. A. M., et al. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02778-6 · Cited by 163
Long-distance modulation of bystander tumor cells by CD8+ T-cell-secreted IFN-γ
Hoekstra, M. E., Bornes, L., Dijkgraaf, F. E., Philips, D., Pardieck, I. N., Toebes, M., Thommen, D. S., van Rheenen, J., & Schumacher, T. N. (2020) · Nature Cancer · doi:10.1038/s43018-020-0036-4 · Cited by 161
Synthetic lethality-mediated precision oncology via the tumor transcriptome
Lee, J. S., Nair, N. U., Dinstag, G., Chapman, L., Chung, Y., Wang, K., Sinha, S., Cha, H., Kim, D., Schperberg, A. V., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.030 · Cited by 158
Future Therapeutic Directions for Smac-Mimetics
Morrish, E., Brumatti, G., & Silke, J. (2020) · Cells · doi:10.3390/cells9020406 · Cited by 159
Self-citationYe, B., Fan, J., Xue, L., Yu, Z., Luo, P., Jiang, A., Xie, J., Li, Q., Liang, X., Tan, J., et al. (2025) · iMeta · doi:10.1002/imt2.70011 · Cited by 152
Natural Killer Cells Suppress T Cell-Associated Tumor Immune Evasion
Freeman, A. J., Vervoort, S. J., Ramsbottom, K. M., Kelly, M. J., Michie, J., Pijpers, L., Johnstone, R. W., Kearney, C. J., & Oliaro, J. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.017 · Cited by 141
Self-citationOvercoming Genetically Based Resistance Mechanisms to PD-1 Blockade
Torrejon, D. Y., Abril-Rodriguez, G., Champhekar, A. S., Tsoi, J., Campbell, K. M., Kalbasi, A., Parisi, G., Zaretsky, J. M., Garcia-Diaz, A., Puig-Saus, C., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1409 · Cited by 146
Zhou, X., Ni, Y., Liang, X., Lin, Y., An, B., He, X., & Zhao, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.915094 · Cited by 145
TISMO: syngeneic mouse tumor database to model tumor immunity and immunotherapy response
Zeng, Z., Wong, C. J., Yang, L., Ouardaoui, N., Li, D., Zhang, W., Gu, S. S., Zhang, Y., Liu, Y., Wang, X., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab804 · Cited by 143
Functional genomics in vivo reveal metabolic dependencies of pancreatic cancer cells
Zhu, X. G., Chudnovskiy, A., Baudrier, L., Prizer, B., Liu, Y., Ostendorf, B. N., Yamaguchi, N., Arab, A., Tavora, B., Timson, R., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2020.10.017 · Cited by 130
“In previously published work, loss of Tap proteins strongly blocks CD8+ T cell-mediated killing of cancer cells in co-culture assays in vitro (Kearney et al., 2018; Patel et al., 2017).”
BackgroundReversal of pre-existing NGFR-driven tumor and immune therapy resistance
Boshuizen, J., Vredevoogd, D. W., Krijgsman, O., Ligtenberg, M. A., Blankenstein, S., de Bruijn, B., Frederick, D. T., Kenski, J. C. N., Parren, M., Brüggemann, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17739-8 · Cited by 124
Oncolytic Parapoxvirus induces Gasdermin E-mediated pyroptosis and activates antitumor immunity
Lin, J., Sun, S., Zhao, K., Gao, F., Wang, R., Li, Q., Zhou, Y., Zhang, J., Li, Y., Wang, X., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-35917-2 · Cited by 126
Cao, X., Geng, Q., Fan, D., Wang, Q., Wang, X., Zhang, M., Zhao, L., Jiao, Y., Deng, T., Liu, H., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-022-01704-8 · Cited by 122
Autophagy protects tumors from T cell–mediated cytotoxicity via inhibition of TNFα-induced apoptosis
Young, T. M., Reyes, C., Pasnikowski, E. M., Castanaro, C., Wong, C. F., Decker, C. E., Chiu, J., Song, H., Wei, Y., Bai, Y., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abb9561 · Cited by 118
Understanding CAR T cell-tumor interactions: Paving the way for successful clinical outcomes
Korell, F., Berger, T. R., & Maus, M. V. (2022) · Med · doi:10.1016/j.medj.2022.05.001 · Cited by 113
Escaping Death: How Cancer Cells and Infected Cells Resist Cell-Mediated Cytotoxicity
Tuomela, K., Ambrose, A. R., & Davis, D. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.867098 · Cited by 111
Falcomatà, C., Bärthel, S., Widholz, S. A., Schneeweis, C., Montero, J. J., Toska, A., Mir, J., Kaltenbacher, T., Heetmeyer, J., Swietlik, J. J., et al. (2022) · Nature Cancer · doi:10.1038/s43018-021-00326-1 · Cited by 108
Antagonism of IAPs Enhances CAR T-cell Efficacy
Michie, J., Beavis, P. A., Freeman, A. J., Vervoort, S. J., Ramsbottom, K. M., Narasimhan, V., Lelliott, E. J., Lalaoui, N., Ramsay, R. G., Johnstone, R. W., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0428 · Cited by 108
Self-citationCucolo, L., Chen, Q., Qiu, J., Yu, Y., Klapholz, M., Budinich, K. A., Zhang, Z., Shao, Y., Brodsky, I. E., Jordan, M. S., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.03.007 · Cited by 104
Roles of RIPK1 as a stress sentinel coordinating cell survival and immunogenic cell death
Clucas, J., & Meier, P. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00623-w · Cited by 105
Pech, M. F., Fong, L. E., Villalta, J. E., Chan, L. J., Kharbanda, S., O’Brien, J. J., McAllister, F. E., Firestone, A. J., Jan, C. H., & Settleman, J. E. (2019) · eLife · doi:10.7554/elife.47362 · Cited by 104
Rewiring endogenous genes in CAR T cells for tumour-restricted payload delivery
Chen, A. X. Y., Yap, K. M., Kim, J. S., Sek, K., Huang, Y., Dunbar, P. A., Wiebking, V., Armitage, J. D., Munoz, I., Todd, K. L., et al. (2025) · Nature · doi:10.1038/s41586-025-09212-7 · Cited by 102
Self-citationAdvancing CAR T-Cell Therapy for Solid Tumors: Lessons Learned from Lymphoma Treatment
Titov, A., Valiullina, A., Zmievskaya, E., Zaikova, E. K., Petukhov, A., Рифкатовна, М. Р., Bulatov, E., & Rizvanov, A. A. (2020) · Cancers · doi:10.3390/cancers12010125 · Cited by 98
Mannion, J., Gifford, V., Bellenie, B. R., Fernando, W., Garcia, L. R., Wilson, R., John, S. W., Udainiya, S., Patin, E. C., Tiu, C., et al. (2024) · Immunity · doi:10.1016/j.immuni.2024.04.025 · Cited by 96
Nguyen, T.-T., Ramsay, L., Ahanfeshar-Adams, M., Lajoie, M., Schadendorf, D., Alain, T., & Watson, I. R. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3365 · Cited by 95
Cui, Y., Li, J., Zhang, P., Yin, D., Wang, Z., Dai, J., Wang, W. T., Zhang, E., & Guo, R. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02711-3 · Cited by 95
TNF Receptor Associated Factor 2 (TRAF2) Signaling in Cancer
Siegmund, D., Wagner, J., & Wajant, H. (2022) · Cancers · doi:10.3390/cancers14164055 · Cited by 95
VDAC2 loss elicits tumour destruction and inflammation for cancer therapy
Yuan, S., Sun, R., Shi, H., Chapman, N. M., Hu, H., Guy, C. S., Rankin, S. L., Anil, K. C., Palacios, G., Meng, X., et al. (2025) · Nature · doi:10.1038/s41586-025-08732-6 · Cited by 94
Dubrot, J., Lane-Reticker, S. K., Kessler, E. A., Ayer, A., Mishra, G., Wolfe, C. H., Zimmer, M. D., Du, P. P., Mahapatra, A., Ockerman, K. M., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.01.001 · Cited by 91
Regulatory mechanisms of PD-L1 expression in cancer cells
Shi, Y. (2018) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-018-2226-9 · Cited by 92
Dufva, O., Gandolfi, S., Huuhtanen, J., Dashevsky, O., Duàn, H., Saeed, K., Klievink, J., Nygren, P. J., Bouhlal, J., Lahtela, J., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.11.008 · Cited by 87
Double-edged effects of interferons on the regulation of cancer-immunity cycle
Zhang, X., Wang, S., Zhu, Y., Zhang, M., Zhao, Y., Yan, Z., Wang, Q., & Li, X. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1929005 · Cited by 85
Chow, R. D.-W., Michaels, T., Bellone, S., Hartwich, T. M. P., Bonazzoli, E., Iwasaki, A., Song, E., & Santin, A. D. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0686 · Cited by 85
Alim, L., Keane, C., & Souza-Fonseca-Guimarães, F. (2023) · Current Opinion in Immunology · doi:10.1016/j.coi.2023.102409 · Cited by 84
Inhibition of UBA6 by inosine augments tumour immunogenicity and responses
(2022) · doi:10.1038/s41467-022-33116-z · Cited by 82
CD4 + T cell immunity against cutaneous melanoma encompasses multifaceted MHC II–dependent responses
Bawden, E., Wagner, T., Schröder, J., Effern, M., Hinze, D., Newland, L., Attrill, G. H., Lee, A. R., Engel, S., Freestone, D., et al. (2024) · Science Immunology · doi:10.1126/sciimmunol.adi9517 · Cited by 82
The proprotein convertase furin in cancer: more than an oncogene
He, Z., Khatib, A., & Creemers, J. W. M. (2022) · Oncogene · doi:10.1038/s41388-021-02175-9 · Cited by 77
Future Challenges in Cancer Resistance to Immunotherapy
van Elsas, M. J., van Hall, T., & van der Burg, S. H. (2020) · Cancers · doi:10.3390/cancers12040935 · Cited by 74
Sethuraman, S. N., Singh, M. P., Patil, G., Li, S., Fiering, S., Hoopes, P. J., Guha, C., Malayer, J. R., & Ranjan, A. (2020) · Theranostics · doi:10.7150/thno.42243 · Cited by 74
Li, J., Wang, H., Wang, Y., Gong, X., Xu, X., Sha, X., Zhang, A., Zhang, Z., & Li, Y. (2020) · Advanced Materials · doi:10.1002/adma.202002380 · Cited by 74
Preedy, M. K., White, M., & Tergaonkar, V. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06559-z · Cited by 73
The Immuno-Modulatory Effects of Inhibitor of Apoptosis Protein Antagonists in Cancer Immunotherapy
Michie, J., Kearney, C. J., Hawkins, E. D., Silke, J., & Oliaro, J. (2020) · Cells · doi:10.3390/cells9010207 · Cited by 73
Self-citationUnleashing TNF cytotoxicity to enhance cancer immunotherapy
Freeman, A. J., Kearney, C. J., Silke, J., & Oliaro, J. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.10.003 · Cited by 71
Self-citationIGSF8 is an innate immune checkpoint and cancer immunotherapy target
Li, Y., Wu, X., Sheng, C., Liu, H., Liu, H., Tang, Y., Liu, C., Ding, Q., Xie, B., Xiao, X., et al. (2024) · Cell · doi:10.1016/j.cell.2024.03.039 · Cited by 70
RNA vaccines for cancer: Principles to practice
Guasp, P., Reiche, C., Sethna, Z. M., & Balachandran, V. P. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.05.005 · Cited by 69
Engineering immune-evasive allogeneic cellular immunotherapies
Martin, K. E., Hammer, Q., Perica, K., Sadelain, M., & Malmberg, K. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01022-8 · Cited by 69
Genome-Wide CRISPR Screen Reveals Cancer Cell Resistance to NK Cells Induced by NK-Derived IFN-γ
Zhuang, X., Veltri, D., & Long, E. O. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02879 · Cited by 65
Glycosylation of Immune Receptors in Cancer
Sun, R., Kim, A. M. J., & Lim, S. (2021) · Cells · doi:10.3390/cells10051100 · Cited by 65
Ou, X., Ma, Q., Yin, W., Ma, X., & He, Z. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.674467 · Cited by 64
Roehle, K., Li, Q., Ventre, K. S., Heid, D., Ali, L. R., Lenehan, P. J., Heckler, M., Crowley, S. J., Stump, C. T., Ro, G., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abf5058 · Cited by 64
Ubiquitin ligase STUB1 destabilizes IFNγ-receptor complex to suppress tumor IFNγ signaling
Apriamashvili, G., Vredevoogd, D. W., Krijgsman, O., Bleijerveld, O. B., Ligtenberg, M. A., de Bruijn, B., Boshuizen, J., Traets, J. J. H., Altimari, D. M. D., Vliet, A. V., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29442-x · Cited by 63
PANoptosis in cancer, the triangle of cell death
Cai, H., Lv, M., & Wang, T. (2023) · Cancer Medicine · doi:10.1002/cam4.6803 · Cited by 60
Inhibition of MAN2A1 Enhances the Immune Response to Anti–PD-L1 in Human Tumors
Shi, S., Gu, S. S., Han, T., Zhang, W., Huang, L., Li, Z., Pan, D., Fu, J., Ge, J., Brown, M. A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0778 · Cited by 60
Loss of Rnf31 and Vps4b sensitizes pancreatic cancer to T cell-mediated killing
Frey, N., Tortola, L., Egli, D., Janjuha, S., Rothgangl, T., Marquart, K. F., Ampenberger, F., Köpf, M., & Schwank, G. (2022) · Nature Communications · doi:10.1038/s41467-022-29412-3 · Cited by 59
CTLA-4 blockade induces tumor pyroptosis via CD8+ T cells in head and neck squamous cell carcinoma
Wang, S., Wu, Z., Zhu, S., Wan, S., Zhang, M.-J., Zhang, B., Yang, Q., Xiao, Y., Li, H., Mao, L., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.02.023 · Cited by 58
Immunotherapy of MSI Cancer: Facts and Hopes
Wilbur, H. C., Le, D. T., & Agarwal, P. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1935 · Cited by 58
Zhang, J., Zhou, K., Lin, J., Yao, X., Ju, D., Zeng, X. L., Pang, Z., & Yang, W. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122395 · Cited by 57
Chen, D., Liu, P., Lu, X., Li, J., Qi, D., Zang, L., Lin, J., Liu, Y., Zhai, S., Fu, D., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03042-7 · Cited by 57
Zhang, Y., Zhao, Y., Li, Q., & Wang, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.685978 · Cited by 57
RNF31 inhibition sensitizes tumors to bystander killing by innate and adaptive immune cells
Zhang, Z., Kong, X., Ligtenberg, M. A., Veen, S. E. V. H.-V., Visser, N. L., de Bruijn, B., Stecker, K. E., van der Helm, P. W., Kuilman, T., Hoefsmit, E. P., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100655 · Cited by 56
Dervovic, D., Malik, A., Chen, E. L. Y., Narimatsu, M., Adler, N., Afiuni‐Zadeh, S., Krenbek, D., Martinez, S., Tsai, R., Boucher, J. G., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38841-7 · Cited by 56
Huang, K. C., Chiang, S., Lin, P.-C., Hong, W.-Z., Yang, P.-C., Chang, H.-P., Peng, S., Chen, T.-W., Ke, T., Liang, J., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-023-06408-5 · Cited by 56
Boumelha, J., de Castro, A., Bah, N. K., Cha, H., Trécesson, S. D. C., Rana, S., Tomaschko, M., Anastasiou, P., Mugarza, E., Moore, C., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-2627 · Cited by 57
Han, X., Zhang, J., Li, W., Huang, X., Wang, X., Wang, B., Gao, L., & Chen, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1512509 · Cited by 56
Li, T., Zhang, W., Niu, M., Wu, Y., Deng, X., & Zhou, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1342647 · Cited by 53
Zhang, W., Zhu, Y., Liu, H., Zhang, Y., Liu, H., Adegboro, A. A., Dang, R., Dai, L., Wanggou, S., & Li, X. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00570-5 · Cited by 53
Metadata
- Authors
- Kearney, C. J., Vervoort, S. J., Hogg, S. J., Ramsbottom, K. M., Freeman, A. J., Lalaoui, N., Pijpers, L., Michie, J., Brown, K. K., Knight, D. A., Sutton, V., Beavis, P. A., Voskoboinik, I., Darcy, P. K., Silke, J., Trapani, J. A., Johnstone, R. W., & Oliaro, J.
- Affiliations
- The University of Melbourne (AU)
- Peter MacCallum Cancer Centre (AU)
- Walter and Eliza Hall Institute of Medical Research (AU)
- Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria 3052, Australia.
- Corresponding author
- Kearney, Conor J.
- Vervoort, Stephin J.
- Johnstone, Ricky W.
- Oliaro, Jane
- ORCID
- Venue
- Science Immunology
- Published
- 2018-05-04
- Volume
- 3
- Issue
- 23
- ISSN
- 2470-9468 (ISSN-L)
- OpenAlex
- W2804568941
- Cited by
- 381
- References
- 46
- Citations by year
- 2026: 20 · 2025: 59 · 2024: 61 · 2023: 59 · 2022: 55 · 2021: 54 · 2020: 38 · 2019: 26 · 2018: 7
- FWCI
- 11.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Victorian Cancer Agency
- National Health and Medical Research Council
- Cancer Council Victoria
- National Breast Cancer Foundation (ECF-17-005)
- Netherlands Organization for Scientific Research
- Peter MacCallum Cancer Foundation
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Keywords
- tumor immune evasion, TNF signaling, T cell-mediated killing, NK cell-mediated killing, interferon signaling, antigen presentation, immune surveillance, tumor immunology
- MeSH terms
- Animals, Interferon-gamma, Killer Cells, Natural, Tumor Necrosis Factor-alpha, Antigen Presentation, CD8-Positive T-Lymphocytes, Tumor Escape, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.